Up to 45 participants will first enter the double-blinded, controlled, randomized clinical trial (RCT) and will self-administer treatments twice daily in the home setting over a period of 24 weeks. Then participants who completed the RCT portion of the study will enter the Open Label Extension (OLE) where all participants will self-administer twice-daily treatments using a treatment mode that previously was shown to be associated with improved cognition in another neurodegenerative disorder. The OLE treatment period will last 24 weeks.
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Alzheimer's disease (AD).